Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

PURPOSE Uterine serous carcinoma (USC) is a distinct histologic subtype of endometrial
cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired …

Simple Summary Mutations in the tumor suppressor p53 (p53) occur in~ 50% of human
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …

Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all,
human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms …

Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …

PURPOSE Preclinical cancer models harboring CCNE1 amplification were more sensitive to
adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we …

Purpose of Review WEE1 inhibitor has been shown to potential chemotherapy or
radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer …

Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous
carcinoma (HGSOC) representing the most common histological subtype. Approximately …

DNA damage response (DDR) is critical to ensure genome stability, and defects in this
signaling pathway are highly associated with carcinogenesis and tumor progression …